• C.R. Bard, Inc. v. Medline Industries, Inc.Rehearing denied
  PTAB · Jul 16, 2015 · IPR2015-00514 · APJ Timothy J Goodson · IPR · Rehearing

  The Board denied rehearing, leaving claims 1–7, 9, and 11–13 instituted and claims 10 and 14–18 denied because Brezette did not teach the claimed first barrier with an opening.

  RulingsRehearing decision

  • RehearingRehearing, deniedDenied

    “misapprehended Petitioner’s argument concerning this limitation. Nowhere in the Petition’s discussion of this limitation does the Petition assert that Brezette’s barrier has a reverse L-shape, as the Request now contends. See Pet. 44–47. Paragraphs 108–09 of Dr. Kimmel’s declaration, which the Petition cites in the discussion of this limitation, also make no reference to an L-shaped barrier in Brezette. Rather, as noted above, Dr. Kimmel’s testimony cited in the Petition is that the claimed barrier in Brezette’s tray is “the wall between the first and second compartment.” Ex. 1002 ¶ 109.” slip op. at 4

  • PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)Not shown unpatentable

    “argument is not persuasive. The face of the wall at the front of Brezette’s lubrication channel 15 is a separate and distinct structure from the wall along the right side of lubrication channel 15. In Figure 1 of Brezette, the portion of Brezette’s tray along the right side of lubrication channel 15 is shown to protrude past the face of the wall at the front of lubrication channel 15. Ex. 1010, Fig. 1. Neither the Petition nor Petitioner’s Request includes any explanation as to why these two distinct features of Brezette should be considered together as the claimed “first barrier.”” slip op. at 5

  None
  Patents in suitUS 8,678,190

Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.